METHOD FOR RADIONUCLIDEAN DIAGNOSTICS OF SECONDARY EDEMATOUS-INFILTRATIVE FORM OF BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU USING RECOMBINANT ADDRESS MOLECULES DARPIN9_29 Russian patent published in 2019 - IPC A61B6/03 A61K51/00 A61K103/10 A61P43/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and radionuclide diagnostics, and can be used for radionuclide diagnostics of secondary edematous-infiltrative form of breast cancer with Her2/neu overexpression using recombinant address molecules DARPin9_29. Injection form of the radiopharmaceutical is introduced on the basis of technetium-99m labeled recombinant address molecules DARPin9_29, which is prepared immediately before administration. For this purpose in aseptic conditions 1 ml of eluate ^99mTcO^4- 7 GBq by means of syringe is added to set for preparation of tricarbonyl technetium and incubated at temperature 100 °C for 30 minutes. After incubation, 1,000 mcl of technetium tricarbonyl is added to 334 mcl of DARPin9_29 at a concentration of the basic substance solution of 3.6 mg/l and incubated at temperature of 40 °C for 60 minutes. Further, the obtained compound is purified from protein impurities and non-technetium-bound DARPin9_29 molecules by means of cleaning columns. Preparation produced after cleansing in dose of 500 MBK is diluted in 10 ml of normal saline and slowly introduced into the patient through a sterilizing filter. In 4 hours after administration of the preparation, a single-photon emission computed tomography is performed on a two-detector gamma camera. Obtained results are evaluated and the malignant tumor is diagnosed when visualizing the RFP fixation in the mammary gland tissues.

EFFECT: higher specificity and informativity and availability of a diagnostic technique for a secondary edematous-infiltrative form of breast cancer with Her2/neu overexpression.

1 cl, 1 dwg, 1 ex